Evidence map›Paper›PMID 37687263›Full record

ReviewMolecules (Basel, Switzerland)2023

Saturated Cannabinoids: Update on Synthesis Strategies and Biological Studies of These Emerging Cannabinoid Analogs.

Maite L Docampo-Palacios, Giovanni A Ramirez, Tesfay T Tesfatsion, Alex Okhovat, Monica Pittiglio, Kyle P Ray, Westley Cruces

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Enzymatic hydrolysis of ∆Forensic toxicology · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maite L Docampo-PalaciosColorado Chromatography Labs, 10505 S. Progress Way, Unit 105, Parker, CO 80134, USA.ORCID 0000-0001-5205-3989
Giovanni A RamirezColorado Chromatography Labs, 10505 S. Progress Way, Unit 105, Parker, CO 80134, USA.
Tesfay T TesfatsionColorado Chromatography Labs, 10505 S. Progress Way, Unit 105, Parker, CO 80134, USA.
Alex OkhovatColorado Chromatography Labs, 10505 S. Progress Way, Unit 105, Parker, CO 80134, USA.
Monica PittiglioColorado Chromatography Labs, 10505 S. Progress Way, Unit 105, Parker, CO 80134, USA.
Kyle P RayColorado Chromatography Labs, 10505 S. Progress Way, Unit 105, Parker, CO 80134, USA.
Westley CrucesColorado Chromatography Labs, 10505 S. Progress Way, Unit 105, Parker, CO 80134, USA.ORCID 0000-0003-3023-7626
Parker Hannifin (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries. A background on the discovery, synthesis, and pharmacology studies of hydrogenated and saturated cannabinoids is described. This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids. A discussion of structure-activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review. According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo. However, the effects of HHC treatment have not been studied in humans, and thus a biological profile has not been established.

Indexed as

CannabinoidsCannabisHallucinogensAnimalsCannabinoid Receptor AgonistsChemical PhenomenaHumansCannabinoid Receptor AgonistsCannabinoidsHallucinogenscannabilactonescannabinoidsCB1 receptorCB2 receptorGPCRhexahydrocannabinolhydrogenationquinones

Identifiers

PMID37687263
PMCPMC10490552
OpenAlexW4386444138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.